Morepen Laboratories Limited has informed the Exchange regarding a revised press release dated May 13, 2025, titled "Morepen Board Proposed Dividend After 23 Years Scores Highest PAT of ₹118 Crore in FY25".
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories has announced a proposed dividend of ₹0.20 per share — its first dividend in 23 years — subject to shareholder approval at the upcoming AGM. The company reported its highest-ever Profit After Tax of ₹118 crore for FY25. Gross revenue rose 7.4% to ₹1,830 crore (from ₹1,704 crore in FY24), while EBITDA grew 11.5% to ₹192 crore. Earnings Per Share climbed 17% to ₹2.20. The API business contributed ₹989 crore, and the Medical Devices segment grew 12% to ₹496 crore, with 72% of API revenue coming from exports to 80+ countries.
The return of dividends after a long gap, combined with record profits and broad-based growth across API and Medical Devices, signals improving financial health and may boost investor sentiment. Shareholders stand to receive a modest payout while benefiting from the company's strongest-ever earnings performance.